Alveus Therapeutics ApS
Private limited companyCVR 44689790København KActive
Alveus Therapeutics ApS is a private limited company, based in København K, active in research and experimental development on natural sciences and engineering, founded in 2024. After a loss in 2024, the company made a profit of DKK 2.1m in 2025. The company is new and has been registered for 2 years. Gross profit is higher than that of 88% of the companies in the industry in the database.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Net profit went from a loss of DKK 5.6m to a profit of DKK 2.1m (2024 → 2025).
- Equity turned positive again: DKK 59.7m (2024 → 2025).
Employees
- 3 more employees than a year earlier: 12 (07/2026) against 9 (07/2025).
Management and owners, last 24 months
- New in management: Rajkumar Kannan (ceo, 30/04/2025), Marie Louise Lindegaard (director, 11/12/2024) and Erik Voorspoels (director, 22/09/2025).
- Stepped down: Lars Peter Brunse (director, 11/12/2024), Nayan Gregory Parekh (ceo, 30/04/2025) and Marie Louise Lindegaard (director, 22/09/2025) (+1).
- New owners registered: FPCI BioDiscovery 7 (22/12/2025), Alveus Therapeutics Inc. (23/01/2026) and Jeito II S.L.P (23/02/2026) (+3).
- No longer registered as owner: Alveus Therapeutics Inc. (21/12/2025) and Alveus Therapeutics Inc. (22/01/2026).
Registrations, last 24 months
- 24/07/2026: Share capital changed from 49,977 DKK to 59,953 DKK
- 23/02/2026: Share capital changed from 45,212 DKK to 49,977 DKK
- 23/01/2026: Share capital changed from 42,978 DKK to 45,212 DKK
- 22/12/2025: Share capital changed from 40,000 DKK to 42,978 DKK
- 03/06/2025: Moved to Palægade 4, 3. th, 1261 København K
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2024–2025 · amounts in DKK thousandEquity and net profit
| 2024 | 2025 | Change | |
|---|---|---|---|
| Revenue | not stated | not stated | – |
| Gross profit | −969 | 22,057 | +2,376.4% |
| Operating profit (EBIT) | −5,608 | 2,720 | +148.5% |
| Profit before tax | −5,608 | 2,097 | +137.4% |
| Net profit | −5,608 | 2,097 | +137.4% |
| Total assets | 480 | 65,129 | +13,468.9% |
| Equity | −5,568 | 59,681 | +1,171.8% |
| Liabilities | 6,048 | 5,448 | −9.9% |
| Cash and cash equivalents | 6 | 63,356 | +1,140,826% |
| Average number of employees | 3 | 2 | −33.3% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Annual reports
2 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 23/06/2026 | The company | PDF not statedXBRL |
| 2024 | 05/03/2024 – 31/12/2024 | 17/06/2025 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 1,317of 69,742 Better than 98% | No. 2,704of 69,964 Better than 96% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 9of 323 Better than 98% | No. 15of 329 Better than 96% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 380of 16,614 Better than 98% | No. 296of 16,661 Better than 98% |
| All companies of type ApS66,508 companies in the comparison | No. 2,166of 66,379 Better than 97% | No. 1,795of 66,505 Better than 97% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Alveus Therapeutics ApSDKK 22.1m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Alveus Therapeutics ApSDKK 2.1m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Alveus Therapeutics ApSDKK 59.7m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Alveus Therapeutics ApS12
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- FPCI BioDiscovery 75% · 0% votes
- Alveus Therapeutics Inc.66.67% · 100% votes
- Jeito II S.L.P5% · 0% votes
- Novo Holdings A/S5% · 0% votes
- Kurma Biofund IV FPCI5% · 0% votes
Management
1 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Rajkumar Kannan | CEO | 30/04/2025 |
- Founders
- New Rhein Healthcare 2021 Lux SCSP, New Rhein Healthcare 2021 de LP
Former management (4)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Lars Peter Brunse | Director | 05/03/2024 | 11/12/2024 |
| Nayan Gregory Parekh | CEO | 05/03/2024 | 30/04/2025 |
| Marie Louise Lindegaard | Director | 11/12/2024 | 22/09/2025 |
| Erik Voorspoels | Director | 22/09/2025 | 15/11/2025 |
Signing rule: Selskabet tegnes af en direktør eller af den samlede direktion.
Address and production units
1 active production unitsPalægade 4
1261 København K
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Alveus Therapeutics ApS | Palægade 4, 3. th, 1261 København K | 12 | 1030169383 |
Purpose
Selskabets formål er at drive virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi.
The purpose is quoted from the register in Danish.
Changes year by year
31 registered events20269 changescapital 3 · ownership 5 · accounts 1
- CapitalShare capital changed from 49,977 DKK to 59,953 DKK
- OwnershipNovo Holdings A/S registered as owner (5%)
- OwnershipKurma Biofund IV FPCI registered as owner (5%)
- AccountsAnnual report for 2025 published
- CapitalShare capital changed from 45,212 DKK to 49,977 DKK
- OwnershipJeito II S.L.P registered as owner (5%)
- CapitalShare capital changed from 42,978 DKK to 45,212 DKK
- OwnershipAlveus Therapeutics Inc. registered as owner (66.67%)
- OwnershipAlveus Therapeutics Inc. is no longer registered as owner
202512 changescapital 1 · ownership 3 · management 5 · accounts 1 · address 1 · industry 1
- CapitalShare capital changed from 40,000 DKK to 42,978 DKK
- OwnershipFPCI BioDiscovery 7 registered as owner (5%)
- OwnershipAlveus Therapeutics Inc. registered as owner (90%)
- OwnershipAlveus Therapeutics Inc. is no longer registered as owner
- ManagementErik Voorspoels stepped down as director
- ManagementErik Voorspoels appointed director
- ManagementMarie Louise Lindegaard stepped down as director
- AccountsAnnual report for 2024 published
- AddressMoved to Palægade 4, 3. th, 1261 København K
- ManagementRajkumar Kannan appointed ceo
- ManagementNayan Gregory Parekh stepped down as ceo
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
202410 changesmanagement 4 · founded 1 · ownership 5
- ManagementMarie Louise Lindegaard appointed director
- ManagementLars Peter Brunse stepped down as director
- FoundedRegistered as Alveus Therapeutics ApS
- ManagementLars Peter Brunse appointed director
- ManagementNayan Gregory Parekh appointed ceo
- OwnershipNew Rhein Healthcare 2021 Lux SCSP registered as owner (50%)
- OwnershipNew Rhein Healthcare 2021 Lux SCSP is no longer registered as owner
- OwnershipAlveus Therapeutics Inc. registered as owner (100%)
- OwnershipNew Rhein Healthcare 2021 de LP registered as owner (33.33%)
- OwnershipNew Rhein Healthcare 2021 de LP is no longer registered as owner
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- Syntese A/Svia Lars Peter Brunse
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.